(UroToday.com) At the metastatic prostate cancer session at the European Association of Urology 2021 annual meeting, Dr. Alexander Kretschmer presented data assessing salvage therapies for PSMA PET/CT-positive node-only recurrent prostate cancer. The role of salvage lymph node dissection in the management of nodal-only recurrent prostate cancer remains controversial. While unfavorable long-term oncological outcomes have cast doubt on the value of salvage lymph node dissection as monotherapy in this clinical setting, comparative data with salvage lymph node radiation therapy as a therapeutic alternative is rare. In addition, the impact on health-related quality of life (HRQOL) has not been adequately evaluated yet. In the current study, Dr. Kretschmer and colleagues analyzed oncological, as well as functional, outcomes of patients with nodal-only recurrent prostate cancer treated with salvage lymph node dissection or salvage lymph node radiation therapy in a single academic tertiary care center.